Clover Health Investments, Corp. (CLOV) MA PPO Plans Earn 5 Stars for 2027
Clover Health (CLOV) announced CMS awarded its Medicare Advantage PPO plans 5 Stars and HMO plan 4.5 Stars for 2027, impacting 2028 payments. 5-Star rating allows year-round PPO enrollment, though CMS noted the PPO rating excludes 20 measures due to a court decision under appeal.
How this was made
The 30-second read
Why it matters
A step-up to 5 Stars for PPO (and 4.5 for HMO) is a concrete quality-rating change for Clover’s MA plans, with a specific operational implication: year-round PPO enrollment. However, the article notes the PPO rating reflects exclusion of 20 measures due to a court decision under appeal, introducing legal/regulatory uncertainty around the rating’s persistence.
Market read
CMS star rating upgrade is a tangible Medicare Advantage catalyst for Clover, potentially supporting enrollment and reimbursement expectations for 2028, but appeal-related exclusions add risk to durability.
What to watch
Traders may be focusing on the star headline while underweighting whether Clover can convert year-round PPO eligibility into sustained membership growth and margin expansion after the appeal process evolves.
Background
CMS assigns Medicare Advantage star ratings that influence plan performance perception and can affect enrollment behavior and payment year dynamics.
Ticker impact
Clover said CMS awarded its 2027 Medicare Advantage PPO plans 5 Stars and HMO 4.5 Stars, impacting payment year 2028 and enrollment rules.
Likely upward bias as markets price improved MA quality metrics and potential enrollment tailwinds, tempered by risk that the court-appeal exclusion changes the rating basis.
The article is a direct CMS rating update tied to 2028 payment year mechanics (5-Star enables year-round PPO enrollment). It also flags that the PPO rating reflects exclusion of 20 measures under a court decision under appeal, which can limit how durable the benefit is.
Market effects
Reinforces that CMS star ratings can materially affect Medicare Advantage plan competitiveness and enrollment dynamics, especially for PPOs.
None specified.
Limited, US Medicare Advantage policy-driven catalyst.
Counterpoint
The 5-Star outcome is partly contingent on exclusions tied to a court decision under appeal, so the market may be overestimating the durability of the rating benefit into 2028.
Key entities
- companyClover Health Investments, Corp.
US Medicare Advantage provider reporting CMS star rating outcomes for 2027 plans affecting payment year 2028.
- regulatorCMS
US Centers for Medicare and Medicaid Services, which assigns Medicare Advantage star ratings.
